SARS‐coronavirus modulation of myocardial ACE2 expression and inflammation in patients with SARS

By G. Oudit, Z. Kassiri, C. Jiang, Peter P. Liu, S. Poutanen, Josef M. Penninger, J. Butany. European Journal of Clinical Investigation, 2009

840 citations recorded by the source corpus.

Background  Angiotensin converting enzyme 2 (ACE2), a monocarboxylase that degrades angiotensin II to angiotensin 1–7, is also the functional receptor for severe acute respiratory syndrome (SARS) coronavirus (SARS‐CoV) and is highly expressed in the lungs and heart. Patients with SARS also suffered from cardiac disease including arrhythmias, sudden cardiac death, and systolic and diastolic dysfunction.

Subfields: Infectious Diseases, Neurology

View Paper: https://www.semanticscholar.org/paper/0294200a5abba339a3b387a1e50583f0576db675

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Infectious Diseases

1. S. Weiss
2. M. Bansal
3. J. Leibowitz

In Neurology

1. M. Bansal
2. Rhian M. Touyz

Citations in the corpus

• Role of angiotensin-converting enzyme 2 (ACE2) in COVID-19 (2020, background): “a more aggressive illness and earlier mortality than those without [47].”
• Coronavirus disease 2019: What we know? (2020, background): “Angiotensin‐converting enzyme 2 (ACE2) was known as cell receptor for SARS‐CoV.(16,23,24) Similar to SARS‐CoV, SARS‐CoV‐2 also use ACE2 as an entry receptor in the ACE2‐expressing cells,(3) indicating SARS‐CoV‐2 may share the same life cycle with SARS‐CoV (Figure 1).”
• Coronavirus Pathogenesis (2011, background): “Furthermore, in a mouse model, SARS-CoV replication in myocardium during pulmonary infection correlated with downregulation of ACE2 in the heart (Oudit et al., 2009).”
• COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options (2020, background): “In murine models, intranasal administration of human SARS-CoV results in ACE2-mediated infection of the myocardium.(109) These observations support a role for SARS-CoV in direct myocardial infection and a possible causative role in cardiac disease subsequent to respiratory infection.”
• Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19) (2020, background): “23 (8-41) days in the group with elevated TnT levels.”
• Cardiovascular disease and COVID-19 (2020, result): “These observations are supported by a previous autopsy study in patients who had died due to SARS during the Toronto SARS outbreak [11].”